diarrhoea induced by HSD-HDC. Prospective controlled trials are needed to confirm its value. Keywords: diarrhoea; high-dose chemotherapy; octreoEmphasis has been put on the intensification of chemotherapy programs through high-dose chemotherapy tide acetate regimens. While their myelosuppression is managed through the use of colony-stimulating factors and/or infusion of autologous peripheral blood progenitor cell Chemotherapy-related diarrhoea is a very common problem transfusions (PBPCT), extramedullary dose-limiting in cancer patients. Although diarrhoea has been reported toxicities, including gastrointestinal mucosal injury, are with many antineoplastic drugs, this adverse effect is usua treatment-limiting factor and their management is a ally associated with 5-FU, 1 CDDP 2 and most recently with critical issue in HSD-HDC. Octreotide is effective in the CPT 11. 3 The diarrhoea associated with high-dose chemocontrol of diarrhoea induced by fluoropyrimidines. We therapy is not only a quality of life issue, but often a lifehave studied its effect on hematopoietic support-depenthreatening toxicity. Mucosal injuries associated with dent high-dose chemotherapy (HSD-HDC) related diawatery diarrhoea result in dehydration, electrolyte disorders rrhoea. HSD-HDC-treated patients were included in the and can be a harbinger of sepsis and neutropenic infections, study when they had у4 loose stools per day. Diagnostic all events which may prolong hospitalization. The successwork-up included physical examination, stool culture, ful management of this toxicity will facilitate the developClostridium difficile toxin assay, abdominal plain films, ment of outpatient intensive chemotherapy programs. complete blood counts, liver and renal function tests.
up to a 0.5 mg/dose and the latter dose was maintained Furthermore, impressive results have been reported with for 24 h. Patients not responding at 0.5 mg/8 h were octreotide acetate in several studies involving 5-fluorouraconsidered failures. A consecutive cohort of 24 HSDcil 9,10 and cisplatin 11 -induced diarrhoea. In a randomized HDC treated patients was studied. Fourteen (n = 14) study in solid tumour patients treated with 5-fluorouracil (58.33%) patients developed severe diarrhoea with a who developed severe diarrhoea, octreotide showed superimedian number of 7.5 loose stools per day (range, 4-ority over loperamide. 
11). Diarrhoea started at a median of 8 days (2-18) from
The present phase II study was designed to evaluate the day 0 of the infusion of HSD-HDC. Seven patients efficacy and tolerance of octreotide in the control of severe (50%) had less than 500 ANC/mm 3 (grade 4 diarrhoea in patients treated with HSD-HDC. neutropenia) simultaneously with the diarrhoea. Twelve of 14 patients (86%) had their diarrhoea controlled, seven of them (50%) at the starting dose level of octreoPatients and methods tide. In five of the responding patients (35.7%), octreotide had to be increased to 0.2 mg (one patient), 0.3 mg (two patients) and 0.5 mg (two patients). No toxicity was
Fourteen consecutive patients treated with a HSD-HDC regimen with colony-stimulating factors and/or peripheral observed, while one patient had a subcutaneous hematoma at the injection site. We have concluded that octreblood progenitor cell transplantation (PBPCT) support, who developed chemotherapy-induced grade 2 diarrhoea (four otide appears to be safe and effective in controlling the to six stools per day, nocturnal stools or moderate cramping), grade 3 (seven to nine stools per day, inconti-Institute, Common Toxicity Criteria (NCI CTC), were Informed consent was obtained for all patients and the protocol was approved by the institutional review board. included in a protocol of escalating doses of octreotide. Number of bowel movements per day were recorded by the patients themselves. Patients with a history of diarrhoea in the month before admission, bowel disease known to cause Results diarrhoea, previous abdominal surgery with dysmotility disorder or short bowel syndrome, pancreatic insufficiency, From March to September 1995, 24 consecutive patients were included for HSD-HDC programs and received 24 graft-versus-host disease, prior abdominal radiation therapy or altered liver function were ineligible.
cycles of chemotherapy (one cycle per patient). Fourteen patients (58.33%) developed grade 2 or greater diarrhoea Every patient underwent a work-up that included physical examination, plain abdominal films, stool cultures for according to NCI CTC and were enrolled in the study, the remaining 10 patients never developed diarrhoea severe common micro-organisms including viruses and Clostridium difficile toxin assay. Patients received one of five HSDenough to be included. All patients were assessable. Patients' characteristics are listed in Table 2 . Drugs, doses HDC disease-oriented protocols (see Table 1 ).
Patients were managed with parenteral hydration and and schedules of HSD-HDC regimens are specified in the Patients and methods section. electrolyte replacement, with no oral intake allowed. All patients were on antibiotics either as part of a prophylactic Diarrhoea started at a median of 8 days (2-18), from the start of the chemotherapeutic regimen, 50% of patients had regimen (ciprofloxacin ± rifampicin) or for treatment of their neutropenic fever (empirically managed with a beta the first episode of diarrhoea during the first week of treatment. Median number of bowel movements at presentation lactam + aminoglycoside + either vancomycin or teicoplanin). Octreotide was administered by means of a was 7.5 per day (4-11), all episodes being watery stools. By the time diarrhoea appeared, 50% of patients had an subcutaneous injection of 0.1 mg three times a day for 2 consecutive days. Patients achieving a complete response ANC over 500 cells/l and 65% had a platelet count over 50 000 cells/l. Ten patients had neutropenic fever, in two (0-2 stools per day) continued treatment for 1 more day. Non-responding patients were treated with a dose increase patients, fever preceded diarrhoea. In all cases, stool cultures were negative, so an infectious aetiology was ruled of 0.1 mg and each successive dose level was sustained for 24 h, until a complete response or toxic effects appeared out. All Clostridium difficile toxin assays were negative. Eight patients had mucositis (50% grade III-IV), in five of or the maximum dose of 0.5 mg q 8 h was reached. In the event of diarrhoea control at any dose level, the treatment them, diarrhoea preceded the appearance of mucositis. There was no relation between severe mucositis and the was continued for 24 h, at the last dose level.
Response criteria were taken from Cascinu et al 12 and number of loose stools or therapeutic response to octreotide. are based on lack of detrimental effect on quality of life with up to two loose bowel movements per day (as deterOverall, 12 patients (85.79%, 95% CI 57.2-98.2%) achieved complete diarrhoea control (the number of loose stools mined by patient interviews) within the framework of an ambulatory HSD-HDC program.
was р2 per day) while on octreotide. Seven patients (50%, 95% CI 27-77%) responded at the first dose level (0.1 mg Patients who relapsed with diarrhoea within 24 h after having finished the protocol were considered failures to the q 8 h). Median stool frequency during the 3 days of therapy with 0.1 mg doses was 3, 1.5 and 1 respectively. Five other treatment and not eligible for a new treatment with octreotide. Data regarding efficacy and side-effects were recorded patients responded to increasing doses of octreotide, as illustrated in Table 3 . Two patients did not respond to octredaily by medical and nursing staff in the inpatient clinic. The clinical activity of octreotide in the management of symptoms associated with a number of secretory diarrhoeal disorders is well documented. [4] [5] [6] [7] 14 Although the exact Table 3 Relation between dose/cumulative response/treatment duration mechanism of action is unknown, a reduction of luminal fluids, the inhibition of chloride secretion with a stimulation contents and the mucosal surface. 16 In watery diarrhoea produced by peptides released by tumors (vipoma, carci- rrhoea, octreotide has been used to treat chemotherapyrelated diarrhoea. Several clinical trials have tested the efficacy of octreotide in the management of severe 5-FUrelated diarrhoea, with high control rates within the first 24 otide, with treatment discontinuation at the dose of 0.5 mg every 8 h and further diarrhoea evolution. Median number h of treatment. 9,10 In a randomized study reported by Cascinu et al 12 octreotide was found to be superior to an opioid of days on octreotide was 6 (range 3-8). Overall, treatment was well tolerated; one patient had a hematoma and pain regimen in controlling 5-FU-induced diarrhoea in patients with solid tumors. Octreotide has also been shown to conin the area of the subcutaneous injection.
trol diarrhoea secondary to cisplatin administration.
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To evaluate the utility of octreotide acetate for the control of HSD-HDC-induced diarrhoea, we conducted this Discussion phase II dose escalation study. The dose and schedule of octreotide were taken from previously published trials. We Diarrhoea is an important toxicity which complicates intensive chemotherapy regimens. Grade 2 or higher diarrhoea chose 0.5 mg three times a day as the maximum dose due to lack of proven efficacy at higher doses, although doses has an incidence as high as 69% in patients with solid tumours treated with similar HSD-HDC programs. 13 of up to 2.0 mg three times a day have been used without toxicity. 17 It remains unclear whether or not there is a doseIn our study, using the National Cancer Institute, Common Toxicity Criteria grade 2 as a cutoff, 14 of the 24 response effect of octreotide in the control of chemo- In conclusion, diarrhoea is a common problem in patients 1194-1195. undergoing HSD-HDC. Octreotide acetate given subcutane-
